The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade
- 28 February 2010
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 116 (2) , 222-233
- https://doi.org/10.1016/j.ygyno.2009.11.001
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01-CA098951, R01-CA112162)
- Ovarian Cancer Research Fund
This publication has 173 references indexed in Scilit:
- Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationCancer Immunology, Immunotherapy, 2009
- Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancerGynecologic Oncology, 2009
- Intraepithelial T cells and tumor proliferationCancer, 2009
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 lossLaboratory Investigation, 2009
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Checkpoint Blockade in Cancer ImmunotherapyPublished by Elsevier ,2006
- The evolution of vertebrate Toll-like receptorsProceedings of the National Academy of Sciences, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- Inflammation and necrosis promote tumour growthNature Reviews Immunology, 2004